» Articles » PMID: 11687030

Domiciliary Oxygen for Interstitial Lung Disease

Overview
Publisher Wiley
Date 2001 Nov 1
PMID 11687030
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Retrospective survival data have suggested poor effectiveness of oxygen therapy in patients with interstitial lung disease (ILD).

Objectives: To determine the effect of domiciliary oxygen therapy on survival and quality of life in patients with a diagnosis of ILD and hypoxaemia.

Search Strategy: Randomized Controlled Trials (RCTs) were identified using the Cochrane Airways Group register and the search terms: (home OR domiciliary AND oxygen AND (Interstitial lung disease OR ILD OR pulmonary fibrosis OR IPF)).

Selection Criteria: Any randomized controlled trial (RCT) in adult patients with hypoxaemia and ILD that compared long term domiciliary or home oxygen therapy with a control group.

Data Collection And Analysis: Only one unpublished RCT was identified.

Main Results: Only one trial was identified. Mortality for both the oxygen treated and control groups was approximately 91% after 3 years (Peto odds ratio 0.99, 95% confidence intervals 0.16,6.26). The effect of oxygen therapy on quality of life and physiological parameters was not reported.

Reviewer's Conclusions: The assumption that home oxygen therapy has a beneficial survival effect in patients with ILD has not been demonstrated in the single RCT identified.

Citing Articles

Non-Pharmacological Management of Idiopathic Pulmonary Fibrosis.

Mullholand J, Grossman C, Perelas A J Clin Med. 2025; 14(4).

PMID: 40004847 PMC: 11856631. DOI: 10.3390/jcm14041317.


Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.

Mackintosh J, Keir G, Troy L, Holland A, Grainge C, Chambers D Respirology. 2024; 29(2):105-135.

PMID: 38211978 PMC: 10952210. DOI: 10.1111/resp.14656.


Cohort study to evaluate prognostic factors in idiopathic pulmonary fibrosis patients introduced to oxygen therapy.

Kataoka K, Oda K, Takizawa H, Ogura T, Miyamoto A, Inoue Y Sci Rep. 2023; 13(1):13664.

PMID: 37608014 PMC: 10444790. DOI: 10.1038/s41598-023-40508-8.


Oxygen in interstitial lung diseases.

Cordeiro R, Nunes A, Smith O, Renzoni E Breathe (Sheff). 2023; 19(1):220271.

PMID: 37378062 PMC: 10292795. DOI: 10.1183/20734735.0271-2022.


Long-term oxygen therapy - Supplement, maintenance, or palliative drug?.

Jindal S Lung India. 2022; 39(2):97-99.

PMID: 35259789 PMC: 9053923. DOI: 10.4103/lungindia.lungindia_74_22.


References
1.
Zielinski J . Long-term oxygen therapy in conditions other than chronic obstructive pulmonary disease. Respir Care. 2000; 45(2):172-6; discussion 176-7. View

2.
Schulz K, Chalmers I, Hayes R, Altman D . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995; 273(5):408-12. DOI: 10.1001/jama.273.5.408. View

3.
Polonski L, Kusnierz B, Krzywiecki A, Polonska A, Tendera M, OKLEK K . [Effects of long term oxygen therapy in patients with idiopathic pulmonary fibrosis. II. Effect of oxygen therapy on function of heart ventricles]. Pol Arch Med Wewn. 1995; 94(4):337-41. View

4.
Braghiroli A, Ioli F, Spada E, Vecchio C, Donner C . LTOT in pulmonary fibrosis. Monaldi Arch Chest Dis. 1993; 48(5):437-40. View

5.
Crockett A, Alpers J, Moss J . Home oxygen therapy: an audit of survival. Aust N Z J Med. 1991; 21(2):217-21. DOI: 10.1111/j.1445-5994.1991.tb00445.x. View